Angiotensin Receptor Blockers ARBs are recommended for all patients with stable angina who also have hypertension, diabetes mellitus, LV ejection fraction 40%, or CKD and have indications for, but are intol- erant of, ACE inhibitors (Class I; Level of Evidence A).169 ARBs are indicated during hospitalization and at discharge for STEMI patients who are intolerant of ACE inhibitors and have HF or an ejection fraction <0.40 (Class I; Level of The combination of ACE inhibitors and ARBs has been used for the treatment of advanced or persistent HF in the convalescent or chronic phase after STEMI,177 but the failed to show additive benefit but with a substantial increase in side effects, so this combination is not recommended. In the VALUE trial,107 there was no difference in cardiac mortality and morbidity in patients with hyperten- sion and high risk of cardiovascular events who were treated with regimens based on valsartan versus amlodipine, even though the BP-lowering effect of amlodipine was greater than that of valsartan. In VALIANT,91 valsartan was as no more effective than captopril in patients who were at high risk for cardiovascular events after MI. Thiazide diuretics and thiazide-like diuretics reduce car- diovascular events, as demonstrated most convincingly in early studies such as the Veterans Administration studies,93 the MRC Trial,94 and in later studies such as These studies included subjects with CAD, and it is a reasonable assumption that diuretics are as effective in the secondary as in the primary prevention of cardiovascular events. 